OncoSil Medical Ltd (ASX: OSL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
OncoSil Medical Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$31.32 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
4.47 billion
Earnings per share
-0.005
Dividend per share
N/A
Year To Date Return
-17.65%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
OncoSil Medical Ltd (ASX: OSL)
Latest News
Healthcare Shares
The OncoSil Medical share price is booming 66%. Here's why
Healthcare Shares
Why is the OncoSil Medical (ASX:OSL) share price surging 18% today?
Healthcare Shares
Why the OncoSil (ASX:OSL) share price finished the day higher today
Share Market News
Here's why the OncoSil Medical (ASX:OSL) share price has jumped 10% today
OSL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About OncoSil Medical Ltd
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.
OSL Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 25 Nov 2024 | $0.01 | $0.00 | 0.00% | 3,523,975 | $0.01 | $0.01 | $0.01 |
| 22 Nov 2024 | $0.01 | $0.00 | 0.00% | 2,524,972 | $0.01 | $0.01 | $0.01 |
| 21 Nov 2024 | $0.01 | $0.00 | 0.00% | 3,074,013 | $0.01 | $0.01 | $0.01 |
| 20 Nov 2024 | $0.01 | $0.00 | 0.00% | 1,373,142 | $0.01 | $0.01 | $0.01 |
| 19 Nov 2024 | $0.01 | $0.00 | 0.00% | 9,545,246 | $0.01 | $0.01 | $0.01 |
| 18 Nov 2024 | $0.01 | $0.00 | 0.00% | 8,685,490 | $0.01 | $0.01 | $0.01 |
| 15 Nov 2024 | $0.01 | $0.00 | 0.00% | 6,814,439 | $0.01 | $0.01 | $0.01 |
| 14 Nov 2024 | $0.01 | $0.00 | 0.00% | 13,149,834 | $0.01 | $0.01 | $0.01 |
| 13 Nov 2024 | $0.01 | $0.00 | 0.00% | 1,950,200 | $0.01 | $0.01 | $0.01 |
| 12 Nov 2024 | $0.01 | $0.00 | 0.00% | 16,890,957 | $0.01 | $0.01 | $0.01 |
| 11 Nov 2024 | $0.01 | $0.00 | 0.00% | 6,204,021 | $0.01 | $0.01 | $0.01 |
| 08 Nov 2024 | $0.01 | $0.00 | 0.00% | 2,475,971 | $0.01 | $0.01 | $0.01 |
| 07 Nov 2024 | $0.01 | $0.00 | 0.00% | 22,090,368 | $0.01 | $0.01 | $0.01 |
| 06 Nov 2024 | $0.01 | $0.00 | 0.00% | 7,448,249 | $0.01 | $0.01 | $0.01 |
| 05 Nov 2024 | $0.01 | $0.00 | 0.00% | 3,428,509 | $0.01 | $0.01 | $0.01 |
| 04 Nov 2024 | $0.01 | $0.00 | 0.00% | 18,371,916 | $0.01 | $0.01 | $0.01 |
| 01 Nov 2024 | $0.01 | $0.00 | 0.00% | 26,254,069 | $0.01 | $0.01 | $0.01 |
| 31 Oct 2024 | $0.01 | $0.00 | 0.00% | 7,448,992 | $0.01 | $0.01 | $0.01 |
| 30 Oct 2024 | $0.01 | $0.00 | 0.00% | 11,880,413 | $0.01 | $0.01 | $0.01 |
| 29 Oct 2024 | $0.01 | $0.00 | 0.00% | 7,188,148 | $0.01 | $0.01 | $0.01 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 19 Dec 2023 | Nigel Lange | Issued | 91,500,000 | $366,000 |
Issue of securities. 96,811,428 Rights, Non-cash
|
| 19 Dec 2023 | Gabriel Liberatore | Issued | 3,000,000 | $21,000 |
Issue of options. Non-cash
|
| 19 Dec 2023 | Doug Cubbin | Issued | 5,000,000 | $35,000 |
Issue of options. Non-cash
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Peter James MacDonald Hall | Non-Executive Director | Oct 2024 |
Mr Hall is a London-based Australian financier, media proprietor and philanthropist. He founded investment firm Hunter Hall Investment Management in 1993, and acted as Chief Investment Officer and Executive Chairman during his 23 year tenure.
|
| Mr Nigel Lange | Chief Executive OfficerManaging Director | Jan 2021 |
Mr Lange brings with him over 30 years of experience in the medical devices industry. Since 2003, Nigel has held leadership roles with Sirtex Medical, a global leader in brachytherapy treatment for liver cancer. From 2003, Nigel served as Chief Executive Officer of Sirtex's European business, responsible for establishing their brachytherapy device in over 300 centres across Europe and the Middle East. Since 2017, Nigel served as Group Chief Commercial Officer where he was responsible for all commercial aspects of the global business. During this time, Nigel has also held interim roles including Interim Group CEO and Interim CEO of Asia Pacific. He is Member of the Risk Committee.
|
| Dr Gabriel Liberatore | Non-Executive Director | Jul 2023 |
Dr Liberatore is an experienced biopharmaceutical executive with over 25 years' experience in senior Business Development, R&D and strategic operational management positions including taking products to market. Until recently, he was the Group Chief Operating Officer at Telix Pharmaceuticals (ASX: TLX) a global biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals. Currently, Dr Liberatore is a Strategic Advisor to GlyTherix Ltd, an Australian immuno-oncology company in developing antibody radiopharmaceuticals for solid tumours. He is Member of the Risk Committee.
|
| Mr Doug Cubbin | Non-Executive Director | Aug 2023 |
Mr Cubbin is an experienced biopharmaceutical executive with over 30 years' experience in senior executive, CFO, Director and Chair roles, across industries. During his tenure as Group Chief Financial Officer at Telix Pharmaceuticals Limited, a global biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals, he was a member of the team which completed the IPO, raised $270 million in capital and grew the business to a multi-billion dollar market capitalisation. Mr Cubbin has also served as Chairman of various boards, including Australian Nuclear Science and Technology Organisation (ANSTO) Nuclear Medicine. He is member of Risk Committee.
|
| Christian Dal Cin | Chief Financial OfficerCompany Secretary | Jun 2023 |
-
|
| Christian Dal Cin | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| BNP Paribas Noms Pty Ltd | 399,120,379 | 11.98% |
| Mrs Sarah Cameron | 184,776,034 | 5.55% |
| Bannaby Investments Pty Limited (Bannaby Super Fund A/C) | 96,000,000 | 2.88% |
| MyConsulting Pty Ltd | 82,500,000 | 2.48% |
| Citicorp Nominees Pty Limited | 75,692,403 | 2.27% |
| Alua Capital Pty Ltd | 67,500,000 | 2.03% |
| Peter Kyros Pty Ltd (Kyros SF A/C) | 64,656,780 | 1.94% |
| Structure Investments Pty Ltd (Rogers Family A/C) | 60,881,945 | 1.83% |
| JK Nominees Pty Ltd (The JK A/C) | 50,000,000 | 1.50% |
| Celtic Capital Pte Ltd (Investment 1 A/C) | 45,000,000 | 1.35% |
| Mrs Lindy Anna Frohnert | 40,540,000 | 1.22% |
| Netwealth Investments Limited (Wrap Services A/C) | 40,117,343 | 1.20% |
| Celtic Finance Corp Pty Ltd | 40,000,000 | 1.20% |
| Tisia Nominees Pty Ltd (Henderson Family A/C) | 38,768,948 | 1.16% |
| Peter James Hall | 38,000,000 | 1.14% |
| Mr Peter Hall | 36,200,000 | 1.09% |
| HSBC Custody Nominees (Australia) Limited | 34,320,539 | 1.03% |
| Mr Gregory Joseph Harris | 32,999,930 | 0.99% |
| Gilman Edwin Wong | 30,000,000 | 0.90% |
| Mr Peter Kyros | 30,000,000 | 0.90% |
